Financing secures path to first NDA submission for buntanetap6-Month symptomatic data readout anticipated Q1 2027Alzheimer’s disease Phase 3 ...

Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses ...

The efzimfotase alfa (ALXN1850) phase III clinical programme, designed to study a broad hypophosphatasia (HPP) patient population, demonstrated positive results. The global clinical programme, which ...

A Structure Therapeutics obesity pill helped patients lose an average of nearly 40 pounds in a mid-stage clinical trial, keeping the drug competitive in the growing crowd of oral medications pursuing ...

OC Transpo officials acknowledged they were considering a full shutdown of the O-Train Line 1 as a contingency plan after a ...

AP01 has completed a phase 1b trial (ATLAS) in idiopathic pulmonary fibrosis (IPF) and has started an open-label extension in ...

While not reaching statistical significance, there was a slowing of disease progression relative to placebo, as measured by ...

An investigative inhaled formulation of the psychedelic mebufotenin is linked to significant improvements in depression symptoms compared to placebo, a phase 2b trial shows.

Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated ...

AL-S Pharma AG, a clinical-stage biotechnology company discovering and developing human antibodies that target misfolded proteins implicated in amyotrophic lateral sclerosis (ALS), today announced the ...

Detailed price information for Pacifica Silver Corp (PSIL-CN) from The Globe and Mail including charting and trades.

Post hoc analyses of pivotal MITIGATE trial show broad efficacy across patient subgroups with differing organ involvement and clinical characteristics.